Nicki Thompson
Chief Executive Officer Trimtech Therapeutics
Seminars
Thursday 10th September 2026
How Seed Stage Biotech Navigate BD Engagement
2:00 pm
- Discussing unique constraints of seed-stage companies when approaching BD engagement
- Maintaining relationships with big pharma and VCs when data is early and limited
- Outlining opportunities for creative deal structures, and when and where they would be appropriate
Thursday 10th September 2026
Expansion Potential: Advancing Degradation into New Indications & Beyond “Classic” Degraders
8:45 am
- Highlighting innovations in non-E3 ligase mechanisms, and discussing which modality fits which disease class?
- Overcoming target identification bottlenecks for immunology and CNS targets. Should companies prioritize diseases with validated pathways but poor druggability, or tissues where degrader PK/ PD is already known?
- As pharma lean towards platforms with broad disease reach, what non-oncology data “moves the needle”?
